KR20120090034A - 이소폼 선택성 포스포리파제 d 저해제 - Google Patents

이소폼 선택성 포스포리파제 d 저해제 Download PDF

Info

Publication number
KR20120090034A
KR20120090034A KR1020127004698A KR20127004698A KR20120090034A KR 20120090034 A KR20120090034 A KR 20120090034A KR 1020127004698 A KR1020127004698 A KR 1020127004698A KR 20127004698 A KR20127004698 A KR 20127004698A KR 20120090034 A KR20120090034 A KR 20120090034A
Authority
KR
South Korea
Prior art keywords
optionally substituted
cycloalkyl
alkyl
compound
alkoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020127004698A
Other languages
English (en)
Korean (ko)
Inventor
에이치. 알렉스 브라운
크레이그 더블유. 린슬리
알렉스 지. 워터슨
세라 에이. 스콧
Original Assignee
벤더르빌트 유니버시티
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 벤더르빌트 유니버시티 filed Critical 벤더르빌트 유니버시티
Publication of KR20120090034A publication Critical patent/KR20120090034A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
KR1020127004698A 2009-07-24 2010-07-23 이소폼 선택성 포스포리파제 d 저해제 Withdrawn KR20120090034A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22849209P 2009-07-24 2009-07-24
US61/228,492 2009-07-24

Publications (1)

Publication Number Publication Date
KR20120090034A true KR20120090034A (ko) 2012-08-16

Family

ID=43499428

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020127004698A Withdrawn KR20120090034A (ko) 2009-07-24 2010-07-23 이소폼 선택성 포스포리파제 d 저해제

Country Status (14)

Country Link
US (1) US9127005B2 (enExample)
EP (1) EP2456307B1 (enExample)
JP (1) JP2013500260A (enExample)
KR (1) KR20120090034A (enExample)
CN (1) CN102573474A (enExample)
AU (1) AU2010275526A1 (enExample)
BR (1) BR112012001586A2 (enExample)
CA (1) CA2768940C (enExample)
IL (1) IL217720A0 (enExample)
IN (1) IN2012DN01661A (enExample)
MX (1) MX2012001064A (enExample)
RU (1) RU2012106657A (enExample)
SG (1) SG178102A1 (enExample)
WO (1) WO2011011680A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN2012DN01661A (enExample) 2009-07-24 2015-06-05 Univ Vanderbilt
CA2850597A1 (en) * 2011-09-30 2013-04-04 Vanderbilt University Antiviral therapies with phospholipase d inhibitors
CA2894843A1 (en) * 2012-12-11 2014-06-19 Vanderbilt University Methods and compositions of treating hiv infection
EP2931277A4 (en) * 2012-12-11 2016-07-27 Univ Vanderbilt PROCEDURE AND COMPOSITIONS WITH ACTIVE INHIBITORS AND / OR PHOSPHOLIPASE D INHIBITORS
CN114778844A (zh) * 2022-03-07 2022-07-22 天津市肿瘤医院（天津医科大学肿瘤医院） Pld1作为评估肿瘤患者对于化疗药物敏感性的分子标志物的用途
CA3258991A1 (en) * 2022-06-16 2025-03-18 Japan Tobacco Inc DIHYDROOXADIAZINONE COMPOUND AND ITS PHARMACEUTICAL USE

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1281502B1 (it) 1995-06-13 1998-02-18 Sardinian Antiviral Research C Impiego di un inibitore non nucleosidico della trascrittasi inversa in associazione con inibitori nucleosidici per il trattamento della
US6187559B1 (en) 1997-08-28 2001-02-13 Novartis Ag Phospholipase D gene
EP1313498A4 (en) 2000-05-25 2004-04-21 Ben-Tsion Williger PHOSPHOLIPASE D EFFECTORS FOR THERAPY AND SCREENING
US6482829B2 (en) * 2000-06-08 2002-11-19 Hoffmann-La Roche Inc. Substituted heterocyclic siprodecane compound active as an antagonist of neurokinin 1 receptor
WO2004026898A1 (en) 2002-09-18 2004-04-01 Postech Foundation Peptide complexes containing phospholipase d
BRPI0517423A (pt) * 2004-12-27 2008-10-07 Astrazeneca Ab composto, composição farmacêutica, método para o tratamento ou prevenção de distúrbios neurológicos e psiquiátricos associados com disfunção do glutamato em um animal, e, uso em um composto
EP1853539A4 (en) 2005-02-23 2010-04-21 Jack L Arbiser HONOKIOL DERIVATIVES TO TREAT PROLIFERATIVE DISEASES
WO2007134958A1 (en) * 2006-05-18 2007-11-29 F. Hoffmann-La Roche Ag Thiazolo-pyramidine / pyridine urea derivatives as adenosine a2b receptor antagonists
US20100009970A1 (en) 2008-03-19 2010-01-14 Combinatorx (Singapore) Pte. Ltd. Compositions and methods for treatment of viral diseases
WO2010037081A1 (en) 2008-09-29 2010-04-01 Palatin Technologies, Inc. Melanocortin receptor-specific spiro-piperidine compounds
CA2756141A1 (en) 2009-03-31 2010-10-07 Sanofi-Aventis Deutschland Gmbh Drug delivery device body
EP2435563A4 (en) 2009-05-29 2013-10-02 Univ Columbia MODULATION OF PHOSPHOLIPASE D FOR THE TREATMENT OF NEURODEEGENERATIVE DISEASES
IN2012DN01661A (enExample) 2009-07-24 2015-06-05 Univ Vanderbilt
WO2011019498A1 (en) 2009-07-27 2011-02-17 The Trustees Of Princeton University Inhibition of glycerol-3-phosphate acyltransferase (gpat) and associated enzymes for treatment of viral infections
CA2850597A1 (en) 2011-09-30 2013-04-04 Vanderbilt University Antiviral therapies with phospholipase d inhibitors
EP2931277A4 (en) 2012-12-11 2016-07-27 Univ Vanderbilt PROCEDURE AND COMPOSITIONS WITH ACTIVE INHIBITORS AND / OR PHOSPHOLIPASE D INHIBITORS
CA2894843A1 (en) 2012-12-11 2014-06-19 Vanderbilt University Methods and compositions of treating hiv infection

Also Published As

Publication number Publication date
EP2456307B1 (en) 2016-11-02
CN102573474A (zh) 2012-07-11
CA2768940C (en) 2018-03-13
SG178102A1 (en) 2012-03-29
CA2768940A1 (en) 2011-01-27
IL217720A0 (en) 2012-03-29
EP2456307A1 (en) 2012-05-30
EP2456307A4 (en) 2013-01-16
US20120214832A1 (en) 2012-08-23
JP2013500260A (ja) 2013-01-07
US9127005B2 (en) 2015-09-08
AU2010275526A1 (en) 2012-03-15
MX2012001064A (es) 2012-07-17
BR112012001586A2 (pt) 2015-09-01
RU2012106657A (ru) 2013-08-27
IN2012DN01661A (enExample) 2015-06-05
WO2011011680A1 (en) 2011-01-27

Similar Documents

Publication Publication Date Title
US10946018B2 (en) Spirocyclic compounds as tryptophan hydroxylase inhibitors
KR102506324B1 (ko) 알파 v 인테그린 억제제로서의 시클로부탄- 및 아제티딘-함유 모노 및 스피로시클릭 화합물
EP3204359B1 (en) Tetrahydroisoquinoline derivatives
CA3153529A1 (en) Brd9 bifunctional degraders and their methods of use
KR20120090034A (ko) 이소폼 선택성 포스포리파제 d 저해제
KR102281550B1 (ko) 아미노피리딘 유도체 및 이의 선택적 alk-2 억제제로서의 용도
KR20130122531A (ko) Ｍｇｌｕｒ５ 양성 알로스테릭 조절물로서 치환된 ６­메틸니코틴아미드
US20240400553A1 (en) Amine based matriptase 2 inhibitors and uses thereof
HK1225720B (en) Spirocyclic compounds as tryptophan hydroxylase inhibitors
BR112016004909B1 (pt) Compostos espirocíclicos como inibidores de triptofano hidroxilase, composição farmacêutica e seus usos

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20120223

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid